Time-Response EEG activity of SR9009 during the dark phase Mice were dosed with SR9009 at different time points (ZT15, ZT18, ZT21) on separate days in order to generate a Time-Resp... by Ariadna Amador (2560231)

Parametric analysis of evoking KCs by directly versus indirectly depolarizing RE. by Rachel A. Mak-McCully (634502)

“…B, When stimulating 6 PY neurons projecting to all RE neurons, the spindling in all three populations drops 100 ms after stimulation is applied at a level of 20pA or higher (red asterisk). …”

Workflow of the study. by Yasir Ali (799969)

“…Our bioinformatics analysis showed significant structural differences for wild type and mutant protein (TM-scores and RMSD values were 0.85934 and 2.34 for rs2397084 (E126G), 0.87388 and 2.49 for rs11465553 (V155I), and 0.86572 and 0.86572 for rs763780 (H161R) with decrease stability for the later. …”

Bioinformatic analyses of <i>IL-17F</i> gene. by Yasir Ali (799969)

“…Our bioinformatics analysis showed significant structural differences for wild type and mutant protein (TM-scores and RMSD values were 0.85934 and 2.34 for rs2397084 (E126G), 0.87388 and 2.49 for rs11465553 (V155I), and 0.86572 and 0.86572 for rs763780 (H161R) with decrease stability for the later. …”

Statistical models used in association analysis. by Yasir Ali (799969)

“…Our bioinformatics analysis showed significant structural differences for wild type and mutant protein (TM-scores and RMSD values were 0.85934 and 2.34 for rs2397084 (E126G), 0.87388 and 2.49 for rs11465553 (V155I), and 0.86572 and 0.86572 for rs763780 (H161R) with decrease stability for the later. …”

Details of amino acid changes in the <i>IL17-F</i> gene. by Yasir Ali (799969)

“…Our bioinformatics analysis showed significant structural differences for wild type and mutant protein (TM-scores and RMSD values were 0.85934 and 2.34 for rs2397084 (E126G), 0.87388 and 2.49 for rs11465553 (V155I), and 0.86572 and 0.86572 for rs763780 (H161R) with decrease stability for the later. …”

Data Sheet 1_Global, regional, and national burden and trends of intracerebral hemorrhage among adolescents and young adults aged 15–39 years from 1990 to 2021: a comprehensive tre... by Xuanchen Liu (12188147)

“…Prevalence rates also decreased from 124.44 to 94.58 per 100,000. Mortality rates and DALYs exhibited similar downward trends. …”

The goal-reaching success rate 〈<i>P</i>_<i>R</i>〉 as a function of motion noise <i>D</i>_<i>m</i> and neural noise <i>D</i>_<i>s</i>. by Shogo Yonekura (4672330)

“…As shown in panels <b>(C)</b> and <b>(F)</b>, if <i>K</i> is large enough to realize a 100% success rate, the <i>P</i>_<i>R</i> monotonically decreases with <i>D</i>_<i>m</i>. …”

The effect of the genetic deletion of P2rx7 on ATP-evoked tritiated (A, C) and endogenous (B) glutamate efflux (D) mRNA expression and (E–I) immunofluorescence staining of the NR2B... by Cecilia Csölle (425362)

“…After a 60-min preperfusion, the basal extracellular [³H]Glu efflux was lower in P2rx7−/− mice. 6-min perfusion of ATP (10 mM) resulted in a transient increase in the efflux of [³H]Glu in P2rx7+/+ mice, which peaked at 6 min after ATP administration and gradually decreased to baseline levels after 12 min. …”

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 co... by Alize J, Ferrari

“…Non-communicable diseases contributed 1·73 billion (95% UI 1·54–1·94) DALYs in 2021, with a decrease in age-standardised DALY rates since 2010 of 6·4% (95% UI 3·5–9·5). …”
Get full text
Get full text
Get full text

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 co... by Alize J, Ferrari

“…Non-communicable diseases contributed 1·73 billion (95% UI 1·54–1·94) DALYs in 2021, with a decrease in age-standardised DALY rates since 2010 of 6·4% (95% UI 3·5–9·5). …”
Get full text
Get full text
Get full text

Image 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…However, the PIBC group exhibited a higher incidence of grade 3–5 AEs, serious AEs, grade 3–5 treatment-related AEs (TRAEs) and serious TRAEs. …”

Table 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…However, the PIBC group exhibited a higher incidence of grade 3–5 AEs, serious AEs, grade 3–5 treatment-related AEs (TRAEs) and serious TRAEs. …”

Image 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…However, the PIBC group exhibited a higher incidence of grade 3–5 AEs, serious AEs, grade 3–5 treatment-related AEs (TRAEs) and serious TRAEs. …”

Table 7_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…However, the PIBC group exhibited a higher incidence of grade 3–5 AEs, serious AEs, grade 3–5 treatment-related AEs (TRAEs) and serious TRAEs. …”

Table 8_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…However, the PIBC group exhibited a higher incidence of grade 3–5 AEs, serious AEs, grade 3–5 treatment-related AEs (TRAEs) and serious TRAEs. …”

Table 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…However, the PIBC group exhibited a higher incidence of grade 3–5 AEs, serious AEs, grade 3–5 treatment-related AEs (TRAEs) and serious TRAEs. …”

Image 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…However, the PIBC group exhibited a higher incidence of grade 3–5 AEs, serious AEs, grade 3–5 treatment-related AEs (TRAEs) and serious TRAEs. …”

Table 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…However, the PIBC group exhibited a higher incidence of grade 3–5 AEs, serious AEs, grade 3–5 treatment-related AEs (TRAEs) and serious TRAEs. …”

Table 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…However, the PIBC group exhibited a higher incidence of grade 3–5 AEs, serious AEs, grade 3–5 treatment-related AEs (TRAEs) and serious TRAEs. …”